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Pericentrin anchors protein kinase A at the centrosome through
a newly identified RII-binding domain 
Dario Diviani*, Lorene K. Langeberg*, Stephen J. Doxsey† and John D. Scott*
Centrosomes orchestrate microtubule nucleation and
spindle assembly during cell division [1,2] and have
long been recognized as major anchoring sites for
cAMP-dependent protein kinase (PKA) [3,4].
Subcellular compartmentalization of PKA is achieved
through the association of the PKA holoenzyme with
A-kinase anchoring proteins (AKAPs) [5,6]. AKAPs have
been shown to contain a conserved helical motif,
responsible for binding to the type II regulatory subunit
(RII) of PKA, and a specific targeting motif unique to
each anchoring protein that directs the kinase to
specific intracellular locations. Here, we show that
pericentrin, an integral component of the pericentriolar
matrix of the centrosome that has been shown to
regulate centrosome assembly and organization,
directly interacts with PKA through a newly identified
binding domain. We demonstrate that both RII and the
catalytic subunit of PKA coimmunoprecipitate with
pericentrin isolated from HEK-293 cell extracts and that
PKA catalytic activity is enriched in pericentrin
immunoprecipitates. The interaction of pericentrin with
RII is mediated through a binding domain of 100 amino
acids which does not exhibit the structural
characteristics of similar regions on conventional
AKAPs. Collectively, these results provide strong
evidence that pericentrin is an AKAP in vivo. 
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Results and discussion
We isolated a cDNA encoding a 436 amino-acid fragment
of pericentrin using an interaction cloning strategy to
identify AKAPs [7]. Pericentrin is a highly conserved com-
ponent of the centrosomal matrix that plays a critical role
in centrosome assembly and spindle integrity [8]. Evi-
dence that pericentrin binds the PKA holoenzyme was
provided by the transient transfection of the haemagglu-
tinin (HA)-tagged protein in HEK-293 cells (Figure 1a,
left panel). A 220 kDa RII-binding protein was detected
after immunoprecipitation of recombinant pericentrin
with anti-pericentrin antibodies (Figure 1a, right panel).
In pericentrin immunoprecipitates, the specific activity of
PKA was enriched 23 ± 3.5 fold (n = 3) over that of the
preimmune control (Figure 1c,d). Immunoprecipitation of
endogenous pericentrin from untransfected cells signifi-
cantly enriched kinase activity by 3.2 ± 0.5 fold (n = 3)
(Figure 1c,d). These values are similar to those obtained
after the immunoprecipitation of other AKAP–PKA com-
plexes from tissues or cell extracts [9,10]. Additional
experiments demonstrated the presence of both the regu-
latory (RII) and catalytic subunits of the PKA holoenzyme
when endogenous pericentrin was immunoprecipitated
from HEK-293 cells (Figure 1b). Collectively, these data
demonstrate that pericentrin functions as an AKAP inside
cells and fulfil recent criteria that have been proposed to
more stringently define AKAPs [6]. 
The RII-binding determinants on all AKAPs identified to
date are contained within a stretch of approximately 20
amino acids that forms an amphipathic helix [11–13].
Therefore, a family of human pericentrin fragments were
screened to map the RII-binding domain (Figure 2a). Sur-
prisingly, an entire region of 100 amino acids between
residues 220 and 320 was necessary for RII binding
(Figure 2b). This finding was confirmed by the generation
of a mouse pericentrin deletion mutant (pericentrin
∆113–213) that lacked these residues (Figure 1a, left
panel). The truncated recombinant pericentrin did not
bind RII in the overlay assay (Figure 1a, right panel) or
coimmunoprecipitate PKA catalytic activity over endoge-
nous levels when overexpressed in HEK-293 cells
(Figure 1c,d). These results infer that pericentrin is a non-
conventional AKAP, which binds RII through a newly
identified binding domain of 100 amino acids. 
Structural studies have shown that the AKAP-binding
determinants are located within the first 45 residues of the
RII molecule [13]. Moreover, mutation of isoleucine
residues at positions 3 and 5 of RIIα completely inhibits the
interaction with AKAPs [14]. In order to demonstrate that
pericentrin interacts with the same AKAP-binding determi-
nants, a series of overlays were performed with various RII
forms as competitors. A fragment containing the first
45 amino acids of RIIα competitively antagonized the inter-
action between RII and the pericentrin fragment encom-
passing the first 436 residues of the protein (Figure 2c). In
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contrast, a RIIα mutant in which the isoleucines at posi-
tions 3 and 5 were mutated to serines did not inhibit RII
binding (Figure 2c). Identical results were obtained when
competition experiments were performed using the
220–320 fragment of pericentrin (data not shown). These
studies confirm that pericentrin and other conventional
anchoring proteins recognize the same structural determi-
nants on RII.
A striking feature of the RII-binding region in pericentrin
is the presence of repeat sequences that are rich in leucine
and valine (Figure 3a). Moreover, hydrophobic interactions
have been shown to mediate the association between RII
and AKAPs [13,14]. To test whether these side chains par-
ticipate in RII binding, clusters of leucine and valine
residues between positions 220 and 320 of the human peri-
centrin fragment were sequentially mutated (Figure 3b–j).
Substitution of leucine residues with proline between
residues 228 and 247 completely abolished RII binding, as
assessed by the overlay assay (Figure 3b–d). Single proline
substitutions of leucine 230, 235 or 245 also abolished
interaction with RII (Figure 3e–g). Likewise, replacement
of these residues with alanine also abolished RII binding,
whereas alanine substitution of adjacent residues had no
effect on anchoring, indicating that the leucine residues at
positions 230, 235 and 245 are specific PKA-anchoring
determinants (Figure 3h–j). This confirms the role of
hydrophobic side-chains located between residues 228 and
247 of pericentrin as determinants for RII anchoring
(Figure 3h–j). Unlike other AKAPs, however, this region is
not predicted to form an amphipathic helix and additional
determinants for interaction with RII lie outside this
region. This is supported by evidence that proline substi-
tutions at leucine clusters between residues 260 and 289
diminished RII binding by 80–90% (Figure 3b–d). These
results suggest that leucine repeat sequences located
between residues 228 and 288 of pericentrin form an inter-
active surface with the regulatory subunit dimer of PKA. 
Over the past decade, AKAPs have emerged as a family of
functionally related proteins that tether the PKA holo-
enzyme and other signaling enzymes to cellular organelles
and membranes [5,6]. These proteins are classified on the
basis of their ability to co-purify with the PKA holoenzyme
from tissue or cell lysates. Our data clearly show that 
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Figure 1
Pericentrin is an A-kinase anchoring protein. (a) HEK-293 cells grown
in 100 mm dishes were transfected with 5 µg of
HA–pericentrin/pcDNA1Amp [17] or HA–pericentrin ∆113–213/
pcDNA1Amp construct. Cells were harvested 24 h after transfection
and lysed in ice-cold hypotonic lysis buffer (20 mM HEPES pH 7.4,
20 mM NaCl, 5 mM EDTA, 5 mM EGTA, 0.1% Triton X-100 (w/v),
1 mM benzamidine, 2 µg/ml pepstatin, 2 µg/ml leupeptin and 1 mM
AEBSF) and subsequently sonicated for 30 sec. Lysates were spun at
100,000 × g for 30 min and 500 µg of supernatant was then subjected
to immunoprecipitation with preimmune or anti-pericentrin immune sera
[19]. Immunoprecipitated complexes were separated by SDS–PAGE
(4–15%) and electrotransferred to nitrocellulose. The recombinant
proteins were detected with a polyclonal anti-HA antiserum (left panel)
or subjected to an RII-overlay assay (right panel). For [32P]RII overlays,
the filters were blocked for 1 h with Blotto + 1% bovine serum albumin
(BSA) in TBS buffer at room temperature and then incubated for
4–16 h with 100,000 cpm/ml of PKA-phosphorylated [32P]RII in Blotto
+ 0.1% BSA. (b) Lysates prepared from untransfected HEK-293 cells
were subjected to immunoprecipitation with preimmune or anti-
pericentrin immune sera. Immunoprecipitates were separated by
SDS–PAGE (4–15%) and electrotransferred to nitrocellulose.
Pericentrin, RII and the C subunit of PKA (PKAc) were detected by
immunoblotting using an affinity-purified rabbit polyclonal antibody
(upper panel), a monoclonal anti-RII antibody (middle panel), and a
monoclonal anti-C subunit antibody (lower panel), respectively.
(c,d) Pericentrin was immunoprecipitated from HEK-293 cell extracts
(endogenous pericentrin), cells transfected with the full-length protein
(recombinant pericentrin), and cells expressing the pericentrin deletion
mutant (pericentrin ∆113–213). Control immunoprecipitates were
performed on each sample using non-immune IgG (Pre-I). Each
immunoprecipitate (Anti-PC) was incubated with cAMP (1 mM) and
assayed for kinase activity in the absence (–) and presence (+) of 4 µM
PKA inhibitor (PKI). The results are expressed as mean ± standard error
(SE) of three independent experiments. Statistical significance was
analyzed by paired Student’s t test: *p < 0.05 as compared to the PKA
activity measured in control immunoprecipitates from untransfected
cells; **p < 0.01 as compared to the PKA activity measured in control
immunoprecipitates from pericentrin transfected cells. 
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pericentrin fulfils this criterion. Interaction with the PKA
holoenzyme is mediated by protein–protein interactions
between a binding site formed by the regulatory subunit
dimer of PKA and a specialized region on the anchoring
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Figure 2
Pericentrin interacts with RII through a newly identified binding domain.
(a) Schematic representation of the human pericentrin fragments used
in mapping the RII-binding site. Interacting fragments are shaded and
the RII-binding domain is indicated (black box). The first and the last
residues of each fragment are indicated. (b) Recombinant pericentrin
protein fragments were expressed from the pET30 (Novagen) vector
as His6-tagged fusion proteins, separated by electrophoresis on
4–15% SDS–PAGE gels and transferred to nitrocellulose membrane.
Each fragment was detected with monoclonal antibodies against the
His6-tag epitope (left panel) and tested for solid-phase RII binding by
overlay assay (right panel). (c) Overlay competition assay for the
interaction between RII and pericentrin. Purified human pericentrin
1–436 fragments (1 µg) were separated by SDS–PAGE (4–15%),
electrotransferred to nitrocellulose and subjected to RII-overlay assay
in the absence or presence of 500 nM RIIα, RIIα1–45, RIIα I3S/I5S or
anchoring inhibitor fragment Ht31 [16], as indicated. The results
shown in (b,c) are representative of three independent experiments. 
Figure 3
Characterization of the RII-binding surface of pericentrin. (a) Schematic
representation of the RII-interacting surface of human pericentrin.
The amino-acid sequence (in single-letter code) between residues
227 and 312 is indicated. Side chains that were changed by site-
directed mutagenesis are indicated by bullet points. A series of
mutants of the pericentrin 1–436 fragment were produced. The
bacterially expressed His6-tagged proteins were affinity purified on
a nickel resin, separated by electrophoresis on 4–15% SDS–PAGE
gels, electrotransferred to nitrocellulose and tested for RII binding by
overlay assay. (b,e,h) RII-overlay assays. (c,f,i) Detection of the
fragments with monoclonal antibodies against the His6-tag epitope.
(d,g,j) Quantitation of the binding by phosphoimage analysis. The
results shown in (d,g,j) are expressed as mean ± SE of three
independent experiments. 
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protein. A variety of structural studies have defined the
RII-binding region of conventional AKAPs as a short helix
which has a hydrophobic face that interacts with the regula-
tory subunit dimer [11,12,15,16]. These regions of approxi-
mately 24 residues contain clusters of branched
hydrophobic side chains such as leucine or isoleucine
[11,13]. The mapping and mutagenesis studies presented
in Figures 2 and 3 suggest that pericentrin shares some but
not all of the characteristics of a conventional AKAP.
Leucine residues located between positions 228 and 268
are required for PKA anchoring; overlay competition exper-
iments indicate that pericentrin binds to the same regions
on RII as other AKAPs. Other characteristics of the RII-
binding region are, however, unique. The RII-binding
determinants are located over an extended region of
100 amino acids and secondary structure predictions do not
indicate the probability of helices within this region. Thus,
the RII-binding region on pericentrin is likely to adopt a
conformation that is distinct from the corresponding regions
on other AKAPs. 
Pericentrin is an integral centrosomal protein that directs
centrosome assembly by binding dynein complexes
[17,18] and regulates microtubule nucleation through
association with γ-tubulin [19]. We can now ascribe an
additional function to the molecule, namely, to anchor the
PKA holoenzyme at this site. As pericentrin is an integral
component of the pericentriolar matrix and clearly plays a
pivotal role in the organization of mitotic spindles [8,19], it
is likely to be a viable candidate for directing PKA toward
centrosomal substrates that are as yet undefined. Interest-
ingly, another PKA-anchoring protein of unknown func-
tion called AKAP350/450/CG-NAP is detected at the
centrosome and may participate in the regulation of PKA
function [20–22]. AKAP350 is not exclusively a centroso-
mal protein, however, and is detected in the Golgi area
and midbody of most cells [20–22]. This raises the intrigu-
ing possibility that pericentrin and AKAP350 might direct
individual PKA pools to precise sites within the centro-
some to modulate distinct centrosomal functions. Alterna-
tively, both anchoring proteins might maintain unique
complements of signaling enzymes, as biochemical studies
have mapped distinct regions of CG-NAP that interact
with PKA, the Rho-dependent kinase PKN and the phos-
phatases PP-1 and PP2A. Future studies will focus on elu-
cidating a role for these individual pools of anchored PKA
and other signaling enzymes at the centrosome.
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